

 참고 문헌

1. Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. *J Clin Endocrinol Metab* 1992;74:577-84.
2. Brue T, Delemer B. Diagnosis and management of hyperprolactinemia: expert consensus - French Society of Endocrinology. *Ann Endocrinol (Paris)* 2007;68:58-64.
3. Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. *N Engl J Med* 1981;304:156-8.
4. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. *Pharmacogenet Genomics* 2009;19:373-82.
5. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. *Clin Endocrinol (Oxf)* 2006;65:265-73.
6. Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. *J Clin Endocrinol Metab* 1995;80:2342-6.
7. Chattopadhyay A, Bhansali A, Masoodi SR. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. *Pituitary* 2005;8:147-54.
8. Chang S, Copperman AB. New insights into human prolactin pathophysiology: genomics and beyond. *Curr Opin Obstet Gynecol* 2019;31(4):207-11.
9. Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. *Best Pract Res Clin Endocrinol Metab* 2019;33(2):101290. doi:10.1016/j.beem.2019.101290. Epub 2019 Jul 10. PMID: 31326373.
10. Colao A, Annunziato L, Lombardi G. Treatment of prolactinomas. *Ann Med* 1998;30:452-9.
11. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. *Expert Opin Investig Drugs* 2002;11:787-800.
12. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. *Eur J Endocrinol* 2003;148:325-31.
13. Colao A, Savastano S. Medical treatment of prolactinomas. *Nat Rev Endocrinol* 2011;7:267-78.
14. Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. *Eur J Obstet Gynecol Reprod Biol* 1992;44:175-80.
15. Davis JR. Prolactin and reproductive medicine. *Curr Opin Obstet Gynecol* 2004;16:331-7.
16. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. *Eur J Endocrinol* 2009;160:747-52.
17. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. *Clin Endocrinol(Oxf)* 2000;53:53-60.
18. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutics strategy. *J Clin Endocrinol Metab* 2001;86:5256-61.
19. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Fac-

- ciolli G, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. *J Clin Endocrinol Metab* 1998;83:807-13.
20. Divers WA, Jr, Yen SS. Prolactin-producing microadenomas in pregnancy. *Obstet Gynecol* 1983;62:425-9.
21. Fahie-Wilson MN, John R, Ellis AR. Macroprolactin: high molecular mass forms of circulating prolactin. *Ann Clin Biochem* 2005;42:175-92.
22. Fideleff HL, Boquete HR, Sequera A, Suarez M, Sobrado P, Giaccio A. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. *J Pediatr Endocrinol Metab* 2000;13:261-7.
23. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. *J Clin Endocrinol Metab* 2005;90:3927-32.
24. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. *Endocr Rev* 2006;27:485-534.
25. Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. *Am J Med* 1988;85:217-20.
26. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. Effects of anti-prolactin autoantibodies on serum prolactin measurements. *Eur J Endocrinol* 1994;130:434-7.
27. Hauache OM, Rocha AJ, Maia AC, Jr., Maciel RM, Vieira JG. Screening for macroprolactinaemia and pituitary imaging studies. *Clin Endocrinol (Oxf)* 2002;57:327-31.
28. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. *Clin Endocrinol (Oxf)* 1996;45:299-303.
29. Karagianis JL, Baksh A. High-dose olanzapine and prolactin levels. *J Clin Psychiatry* 2003;64:1192-4.
30. Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. *Clin Endocrinol (Oxf)* 2001;54:295-300.
31. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. *J Clin Endocrinol Metab* 1996;81:4358-65.
32. Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone-associated hyperprolactinemia. *Endocr Pract* 2000;6:425-9.
33. Klibanski A. Clinical practice. Prolactinomas. *N Engl J Med* 2010;362:1219-26.
34. Kukstas LA, Domec C, Bascles L, Bonnet J, Verrier D, Israel JM, et al. Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterised by the irresponsive to dopamine, and modification of expression by sex steroids. *Endocrinology* 1991;129:1101-3.
35. Lebbe M, Hubinont C, Bernard P, Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. *Clin Endocrinol (Oxf)* 2010;73:236-42.
36. Littlely MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. *Q J Med* 1989;70:145-60.
37. Losa M, Mortini P, Barzagli R, Gioia L, Giovannelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. *J Clin Endocrinol Metab* 2002;87:3180-6.
38. Mann WA. Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach. *Eur J Clin Invest* 2011;41:334-42.
39. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. *J Clin Invest* 2003;112:1603-18.
40. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96:273-88.
41. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. *Clin Endocrinol (Oxf)* 1994;41:359-64.
42. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. *J Clin Endocrinol Metab* 1985;60:698-705.
43. Molitch ME. Pharmacologic resistance in prolactinoma patients. *Pituitary* 2005;8:43-52.
44. Naidich MJ, Russell EJ. Current approaches to imaging of the sellar region and pituitary. *Endocrinol Metab Clin North Am* 1999;28:45-79.
45. Oh JS, Kim HJ, Hann HJ, Kang TU, Kim DS, Kang MJ, Lee JY, Shim JJ, Lee MR, Ahn HS. Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study. *Pituitary* 2021;24(1):38-47.
46. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. *Clin Endocrinol (Oxf)* 1999;51:119-26.
47. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. *J Clin Endocrinol Metab* 2008;93:4721-7.

48. Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. *J Clin Endocrinol Metab* 2002;87:3578-82.
49. Patel SS, Bamigboye V. Hyperprolactinaemia. *J Obstet Gynaecol* 2007;27:455-9.
50. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, et al. Resistance to bromocriptine in prolactinomas. *J Clin Endocrinol Metab* 1989;69: 00-9.
51. Petakov MS, Damjanovic SS, Nikolic-Durovic MM, Dragojlovic ZL, Obradovic S, Gligorovic MS, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. *J Endocrinol Invest* 1998;21:184-8.
52. Prabhakar VK, Davis JR. Hyperprolactinaemia. *Best Pract Res Clin Obstet Gynaecol* 2008;22:341-53.
53. Rigg LA, Lein A, Yen SS. Pattern of increase in circulating prolactin levels during human gestation. *Am J Obstet Gynecol* 1977;129:454-6.
54. Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. *Intern Med* 2001;40:857-61.
55. Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P. Hyperprolactinemia: different clinical expression in childhood. *Horm Res Paediatr* 2010;73:187-92.
56. Schlechte J, Sherman B, Halmi N, VanGilder J, Chapler F, Dolan K, et al. Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study. *Endocr Rev* 1980;1:295-308.
57. Schlechte JA. Update in pituitary 2010. *J Clin Endocrinol Metab* 2010;96:1-8.
58. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. *J Clin Psychopharmacol* 2002;22:109-14.
59. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. *J Clin Endocrinol Metab* 2002;87:5410-5.
60. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. *Clin Endocrinol (Oxf)* 1996;44:305-9.
61. Strachan MW, Teoh WL, Don-Wauchope AC, Seth J, Stoddart M, Beckett GJ. Clinical and radiological features of patients with macroprolactinaemia. *Clin Endocrinol (Oxf)* 2003;59:339-46.
62. Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. *Neurosurgery* 1999;44:254-61;discussion 261-3.
63. Vance ML, Thorner MO. Prolactinomas. *Endocrinol Metab Clin North Am* 1987;16:731-53.
64. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. *J Clin Endocrinol Metab* 1999;84:2518-22.
65. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. *N Engl J Med* 1994;331:904-9.
66. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. *Br J Psychiatry* 2003;182:199-204.
67. Yuen YP, Lai JP, Au KM, Chan AY, Mak TW. Macroprolactin-a cause of pseudohyperprolactinaemia. *HongKong Med J* 2003;9:119-21.